Surgical resection of recurrent upper abdominal cervical cancer: A case report and review of the literature  by Papadia, Andrea et al.
Gynecologic Oncology Reports 1 (2011) 8–9
Contents lists available at SciVerse ScienceDirect
Gynecologic Oncology Reports
j ourna l homepage: www.e lsev ie r .com/ locate /gynorCase Report
Surgical resection of recurrent upper abdominal cervical cancer: A case report and
review of the literature
Andrea Papadia a,⁎, Yesenia Moya a, Steven E. Rodgers b, Joseph A. Lucci III a, John P. Diaz a
a Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA
b Division of Surgical Oncology, Department of General Surgery, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USAa r t i c l e i n f oArticle history:
Received 28 August 2011
Accepted 29 September 2011
Available online 6 October 2011
Keywords:
Cervical cancer
Liver metastates
MetastasectomyIntroduction
The role of surgery in recurrent cervical cancer has traditionally been
conﬁned to patientswith limited, centrally located lesions and restricted
to exenterative procedures. Metastatic disease or recurrent lesions not
amenable to local excision or regional radiation have a poor prognosis,
and are treated with palliative chemotherapy (Monk et al., 2009). We
report a case of a recurrent squamous cell cervical cancer to the abdo-
men that was treated with chemotherapy and metastasectomy involv-
ing left hepatectomy, partial pancreatectomy and partial gastrectomy.
Case report
A 41-year-old female underwent a radical abdominal hysterectomy,
pelvic and para-aortic lymphadenectomy for a FIGO stage IB1 squamous
cell cervical cancer in January 2004. Final pathology demonstrated a
4.7 cm squamous cell carcinoma with deep stromal invasion and
lymph vascular space invasion; parametria, margins of resection and
lymph nodes were free from disease. Based on pathologic risk factors,
we recommended adjuvant radiation therapy with radiosensitizing
cisplatin. The patient was not compliant with the recommendations,
and the treatment was never delivered.
In June 2006, a computer tomography (CT) scan demonstrated a
pelvic recurrence, measuring 6 cm that was obstructing both ureters.⁎ Corresponding author.
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Open access under CC BY-NC-ND license.She was treated with chemo-radiotherapy to the pelvis (45 Gy),
which achieved a complete response on PET/CT. In October 2009, a
CT scan revealed an isolated lesion to the left lobe of the liver invad-
ing into the posterior wall of the stomach and the duodenum (Fig. 1).
A PET scan recorded a SUV of 10 and conﬁrmed the absence of other
lesions. A biopsy conﬁrmed a recurrence, consistentwith squamous cell
carcinoma. Her GOG performance status was 0. The patient was started
on systemic chemotherapy with cisplatin 50 mg/m2 and topotecan
0.75 mg/m2 day 1–3 every 3 weeks (Monk et al., 2009). Dose reduction
and growth factor support were required due to grade 4 bone marrow
toxicity. After four cycles of chemotherapy, CT and PET scan demon-
strated a partial response and no new lesions. Based on the signiﬁcant
bone marrow toxicity resulting in dose reduction and treatment delays
and no evidence of distant metastases, the decision was made to pro-
ceed with a multidisciplinary radical surgical resection. In combination
with surgical oncology, a radical local resection consisting of a left
hepatectomy, partial pancreatectomy and partial gastrectomy was per-
formed. OR timewas 6 h, EBL was 700 ml and no perioperative compli-
cations were recorded. The patient was discharged on post-operative
day # 9. At the time of discharge she was tolerating regular diet, ambu-
lating well and her pain was controlled on p.o. medications. She
returned to normal activitieswithin 6 weeks. Final pathological analysis
revealed a 7.5 cm tumor with negative resection margins. The patient's
postoperative course was uneventful. She received no further adjuvant
therapy, and her bone marrow ultimately recovered. She remained
symptom and disease-free for over 10 months.
Discussion
For patients with extrapelvic recurrent cervical cancer, hence not
treatable with radiation or resectable with an exenteration, palliative
chemotherapy is the mainstay of treatment with a median overall
survival of 12 months (Monk et al., 2009). Prognosis of patients with
recurrence to the liver is poor with a median survival of 10 months
(Kim et al., 1998).
While surgical excision of resectable hepatic metastases from
colo-rectal cancer is considered standard of care, very few case reports
have been published on surgical resection of cervical cancer liver exci-
sion since most of the patients with liver metastases present with
disseminated disease (Kim et al., 1998; Carson et al., 1967). An electronic
search of the PubMed database was performed using the keywords:
“recurrent cervical cancer” and “resection”; “recurrent cervical can-
cer” and “liver”; “recurrent cervical cancer” and “metastasectomy”.
Fig. 1. Large heterogeneous, predominantly hypodense lesion within the left lobe of the
liver. There is no evidence of additional hepatic or extrahepatic lesion neither on CT nor
on PET scan.
Table 1
Summary of literature on surgical management of liver recurrences in cervical
carcinoma.
Author/year N Disease free
interval
Extra-hepatic
metastases
Number and size
of lesions
Overall
survival
Foster
(1978)
3 n.a. n.a. n.a. 14 months,
DOD
n.a. n.a. n.a. 42 months,
DOD
n.a. n.a. n.a. 7 months,
NED
Wolf et al.
(1991)
1 n.a. n.a. Two, 2 cm and
0.1 cm
16 months,
DOD
Kaseki et al.
(1992)
1 41 No Single, 4 cm 22 months
NED
Chi et al.
(1997)
2 18 No Single, 4 cm 50 months,
NED
32 No Single, 4 cm 15 months,
DOD
La Fianza et
al. (1999)
1 39 No Single, 4 cm 22 months,
DOD
Papadia et al.
(2011)
1 41 Single, 7.5 cm 16 months,
AWD
9A. Papadia et al. / Gynecologic Oncology Reports 1 (2011) 8–9English languagewas applied as only limitation to the search. Reference
list of the retrieved articles were examined for additional references.
Manuscripts were selected if they reported on treatment modalities of
recurrent cervical cancer metastatic to the liver. Inmost of the reported
cases in which a liver excision was performed, the lesion was isolated
and relatively small, ≤4 cm. Survival ranged from 7 to 50 months
(Foster, 1978; Kaseki et al., 1992; Chi et al., 1997; Wolf et al., 1991; La
Fianza et al., 1999) (Table 1). In our case, the absence of othermetastatic
lesions was assessed with CT scan, PET scan and intraoperative liver
ultrasound. We decided to treat the patient with chemotherapy prior
to the surgical resection. This may be helpful in making a subsequent
excision less extensive, in assessing in vivo the efﬁcacy of the chemo-
therapeutic regimen and in sterilizing other microscopic areas of
disease. There is no evidence that continuing chemotherapy after a sur-
gical excision with negative margins is of any beneﬁt in malignancies
recurring to the liver.
After surgery, our patient remained asymptomatic and disease free for
10 months. This compares favorablywith a 6 monthmedian progression-
free survival recorded by GOG in recurrent cervical cancer patients
treated with chemotherapy (Monk et al., 2009). During this time our
patient remained off cytotoxic therapy. This proved beneﬁcial to our
patient. During this chemo-free time her bonemarrow function returned
to normal. In addition she reported a return to her normal daily activities.
Unfortunately, she ultimately recurred to the liver with multiple lesions.
The patient has been restarted on chemotherapy with weekly paclitaxel
and is tolerating her therapy well.Historically, patientswhodeveloped distantmetastases from cervical
cancer were not considered eligible for surgical resection. However, in
selected cases with isolated recurrences, well controlled status of the
primary lesion, good performance status and long progression free
survival, a surgical resectionwith negativemargins in amultidisciplinary
approach may provide a long term complete remission alleviating the
need for systemic chemotherapy (thus sparing organ function and che-
motherapeutic options for future relapses) and a survival advantage in
recurrent cervical cancer patients.
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